Arcturus Therapeutics Holdings Inc
ARCT
Company Profile
Business description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Contact
10628 Science Center Drive
Suite 250
San DiegoCA92121
USAT: +1 858 900-2660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
180
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,728.50 | 26.20 | -0.30% |
| CAC 40 | 7,255.42 | 18.53 | 0.26% |
| DAX 40 | 20,016.75 | 83.13 | 0.42% |
| Dow JONES (US) | 44,705.53 | 76.47 | -0.17% |
| FTSE 100 | 8,358.33 | 1.08 | -0.01% |
| HKSE | 19,733.99 | 12.33 | -0.06% |
| NASDAQ | 19,480.91 | 76.96 | 0.40% |
| Nikkei 225 | 39,276.39 | 27.53 | 0.07% |
| NZX 50 Index | 12,896.67 | 196.51 | -1.50% |
| S&P 500 | 6,049.88 | 2.73 | 0.05% |
| S&P/ASX 200 | 8,462.60 | 32.60 | -0.38% |
| SSE Composite Index | 3,364.65 | 14.16 | -0.42% |